News Archive  

*        *        *

 
 

David C. Seldin: Brilliant Scientist, Compassionate Clinician and Gifted Teacher

With sadness we write to let you know that we have lost a distinguished professor, brilliant investigator, beloved physician, and beneficent leader. David C. Seldin, MD, PhD, director of the Amyloidosis Center at Boston University School of Medicine, died on June 27, of prostate cancer. He was 58.

Dr. Seldin devoted his career to clinical and translational research in amyloidosis. He became Director of the Amyloidosis Center in 2007, and the Chief of Section of Hematology-Oncology in 2008. His research interests focused on cancer and blood disorders, particularly the light chain amyloidosis. His research was supported by the American Society of Clinical Oncology, the Howard Hughes Medical Institute, the Leukemia and Lymphoma Society, the Avon Foundation, the Department of Defense, the Wildflower and Gruss Foundations, the Stewart Endowment Fund, the U.S. Health Resources and Services Administration, the Institute of Medicine and the National Institutes of Health through R01 and P01 awards.

David and his colleagues developed a publicly available database of amyloidogenic light chains and the first transgenic model of AL amyloidosis, used to test novel therapies. An active clinical investigator, he served as principal or co-investigator on trials of immunomodulatory drugs, proteasome inhibitors and anti-fibril antibodies for AL amyloidosis. He and his colleagues worked on refining techniques of autologous stem cell transplantation and developing therapies for other forms of amyloidosis. Of greatest impact on his academic career were collaborations with colleagues all over the world. In addition to his research activities, he devoted a large portion of his time training and mentoring generation of physicians and post-doctoral and pre-doctoral fellows in the conduct of clinical, laboratory and translational research. He enjoyed serving on innumerable thesis committees.

Among his many honors, David received the Wesley and Charlotte Skinner Professorship for Research in Amyloidosis in 2014. He was a member of a NIH study section and grant and program review panels for the United States, Canada, Greece, United Kingdom and Singapore. He was the first director of the graduate program in Molecular Medicine in the Division of Graduate Medical Sciences, and established graduate courses in Cancer Biology and in Diseases of Protein Misfolding. He was recognized in a variety of “Best Doctors” lists. He served on the scientific advisory board of the Amyloidosis Foundation, the board of the International Society of Amyloidosis, and as an associate editor of Amyloid, Journal of Protein Folding Disorders. 

During his too short time at Boston Medical Center and Boston University School of Medicine, David had an enormous impact, and the creation of a Boston University Center of Excellence, the Amyloidosis Center, ranks prominently within that impressive legacy. He was the preeminent physician and a tireless advocate to provide access to high quality health care for all.  

David will be remembered as a beacon of hope for his patients, a source of inspiration and a role model for his trainees and with admiration by his colleagues. He will be remembered as one of the most respected researchers, and dedicated to his research – careful, thoughtful and incredibly creative.  Vaishali Sanchorawala, describes him: “David Seldin – Where brilliance meets kindness.” His legacy is unique and he will be much missed by all who know him. 

David is survived by his wife Dr. Elizabeth Hohmann, a specialist in infectious diseases at Massachusetts General Hospital; his three daughters Stephanie, Maggie and Diana; his parents Florence and Ira Seldin of Chatham, Massachusetts; and his sister Judi Seldin of Needham, Massachusetts. A memorial service will be announced when plans are finalized.

 

*        *        *

 
A Geramy symposium was organized in Heidelberg, on 20 and 21 November 2015. GERAMY is the GERman consortium for systemic light chain (AL) AMYloidosis, founded in 2012. One of the aims of this symposium was to present and discuss the results of three years of research by the GERAMY collaborators. It was very successful and many attended this symposium.

Stefan Schönland, Ute Hegenbart, Marcus Fändrich and Erich Wanker

*        *        *

 
The Renal Pathology Society for the 2nd International Meeting of the International Kidney and Monoclonal Gammopathy Research Group (IKMG) met in La Rochelle, France on September 3rd – 4th of 2015.  The purpose of the IKMG is to promote the study and research of monoclonal gammopathy related kidney diseases.  This meeting covered clinical and scientific topics that are at the forefront of this disease group.  There was a session on therapeutics and response measurement in AL amyloidosis.  It is the only meeting of its kind that brings together experts from Nephrology, Hematology, Renal Pathology and basic science.  Details of the provisonal program, costs, lodging and participation could be found by this link and by this powerpoint presentation.

Guy Touchard, Congress President and Nelson Leung, IKMG President

*        *        *

 
The contract between the ISA and Informa, the Publisher of AMYLOID, has been renewed until 2015. Favorable conditions (reduced membership fee and subscription rate) will continue for young investigators. 

Junior investigators (<35 years) are cordially invited to become ISA member & get online access to the Journal at a low annual rate!

 

Investigators may become Member of the ISA and can subscribe in one of three categories:

    Online only ($ 190.00): annual dues ($ 90.00) and e-journal subscription only ($ 100.00)

    Print & Online ($ 230.00): annual dues ($ 90.00) and both paper & e-journal subscription ($ 140.00)

    Young Investigator ($ 90.00) for investigators under age 35: dues ($ 20.00) and e-journal ($ 70.00)

All payments must be in U.S. Dollars.

 

Top reasons to submit to AMYLOID:

Rapid Publication: Your final article is published online in as little as 8 weeks, via our Early Online feature

Online Manuscript Submission: Submit and track the progress of your paper on our online submission site

Citation Alerts: Track citations to your article via our citation alert service

Impact factor in 2011 was 2.660. Ranking: 26/155 (Q1 = top quartile) for Medicine, General & Internal

 

*        *        *

 
Welcome to Brazil! Welcome to Rio de Janeiro!

On behalf of the organizing committee, we sincerely welcome you to the IXth International Symposium on Familial Amyloidotic Polyneuropathy (ISFAP) and the VIIIth International Symposium on Liver Transplantation in Familial Amyloidotic Polyneuropathy, to be held in Rio de Janeiro, Brazil, November 10 to 13, 2013.

These symposia aim to promote a lively discussion around selected aspects of the most recent advances in understanding the mechanisms behind Familial Amyloidotic Polyneuropathy (FAP), as well as new biomarkers and early indicators of disease progression and disease staging, ending with a section devoted to treatments -- including liver transplantation and promising new drugs. We welcome the opportunity to bring together colleagues from Latin America and other regions with investigators from well-known referral centers, with the aim of fostering new and fruitful scientific collaborations.

This is the first time that these symposia will be held outside the well-known research centers of Europe, Japan or the USA. It is a tremendous challenge for us to match the quality of the previous symposia organized by our colleagues, and we look forward to it. We are sure that you will enjoy not only the scientific program but also the beauty of Rio de Janeiro! If we are successful, at the end of the meeting you will understand why we are proud to host this event, and why this city is called “Cidade Maravilhosa”.

Sincerely,

Márcia Waddingon Cruz and Débora Foguel

Organizers

*        *        *

 
The XIIIth International Symposium on Amyloidosis "From misfolded proteins to well-designed treatment" has been held in the University Medical Center of Groningen  (The Netherlands), 6-10 May 2012. There were 420 participants from 33 countries of whom 93 were younger than 35 years present. A total of 36 lectures, 75 oral presentations, 15 selected poster presentations, and 183 posters were presented during the Symposium. There were 24 young scientists who received travel awards and 9 young scientists who received presentation awards.

UMCG gevel

*        *        *

 
The VIIIth International Symposium on Familial Amyloidotic Polyneuropathy & VIIth International Workshop on Liver Transplantation in Familial Amyloidotic Polyneuropathy & IInd International Symposium on Transthyretin will be held 20-23 November 2011 in Kumamoto, Japan.

Dates: Sunday, November 20th to Wednesday, November 23rd, 2011. About 300 participants.

Main venue: Kumamoto City International Center 4-8 Hanabata-cho, Kumamoto-shi 860-0806 Japan Tel: +81- 96- 359- 2020

Contact the Secretariat of the FAP Meeting 2011: Department of Diagnostic Medicine Graduate school of Medical Sciences, Kumamoto University 1-1-1 Honjo Kumamoto 860-8556, Japan, Phone: +81-96-373-5283, Fax: +81-96-362-7540, E-mail: fapmeeting2011@gmail.com

Abstracts can be submitted from 20 June 2011! See the pdf file for more information.

*        *        *

 
Announcement by the President:

January, 2012

Dear Colleagues,

Best wishes for 2012. I have some wonderful news to tell you as we begin this new year. Our London colleague, Mark Pepys, was knighted in this year's UK New Years Honours list for his efforts, outstanding achievements, and continuing contribution to science and medicine. This is an enormous honor and well deserved. Congratulations Sir Mark Pepys!

I hope you are making plans to be at the XIIIth International Symposium on Amyloidosis in Groningen May 6-10, 2012 with Bouke Hazenberg as host. The Symposium in Groningen will be an historic event and a tribute to the late Professor Enno Mandema, host of the First Symposium in Groningen 45 years ago in 1967. The XIIIth Symposium will focus on basic and translational research in a program that will cover all forms of systemic amyloidosis. Information about the program, abstract submission, hotel bookings, and more can be found on the website: www.amyloidosis2012.com

The International Society will hold its business meeting at the Symposium and an important item of business will be the election of officers for the Society. Current officers are listed on this letterhead. Nominations are open for the positions of President-Elect, Secretary, Treasurer, and 3 Members-at-large. Officers are allowed to serve 2 terms and most of the present officers are in their first term. If you would like to nominate an ISA member for a position, please confirm that the member is willing to be nominated and e-mail your nomination to the ISA secretary, Laura Obici: l.obici@smatteo.pv.it.

Laura must receive your nominations by February 1st so that we can prepare an electronic ballot for this election. An electronic ballot will give all members a chance to vote whether or not they plan to attend the Symposium. You will have an opportunity to vote at the Symposium, if you haven’t done so electronically, however, I suggest you use the electronic ballot in case a natural disaster limiting travel occurs again.

Finally, I have some more good news. Merrill Benson has offered to host the next meeting in Indianapolis, Indiana in May, 2014 and his offer has been approved by the Board of Directors. More information will be coming soon.

I am looking forward to seeing you in Groningen. With best wishes,

Martha Skinner, M.D.

President, International Society of Amyloidosis

*        *        *

 
Announcement by the President:

July, 2011

Dear Colleagues,

I hope you are having a good summer. It is time for me to write you again with news of International Society of Amyloidosis and urge you to stay informed by visiting our website. I hope you have continued your membership this year and will invite your colleagues to join. Your membership supports the ISA International meetings and includes a subscription to the Amyloid Journal which now offers early on-line access to published articles. Directions for joining are found on our website. In a small Society every member counts!

Our journal, Amyloid: the journal of protein folding disorders, is thriving under the capable editorship of Per Westermark. I urge you to submit your manuscripts to our Amyloid journal. The on-line submission and review process has a fast turnaround time. You can access directions for on-line submission on our website. This is the only journal devoted to research and treatment of amyloid diseases and it is widely read by our membership. Per has asked me to advise you of the importance of citing references from Amyloid as you write manuscripts for submission to any journal. The number of references to published articles in Amyloid determines the "impact factor", a critically important measure of the Journal’s status. The impact factor is measured each year based on published citations in the preceding 2 years.

Two important meetings are coming up. The XIIIth International Symposium on Amyloidosis "From misfolded proteins to well-designed treatment" will take place at the University Medical Center of Groningen, the Netherlands May 6-10, 2012. As you may know Groningen was the site of the First Symposium in 1967, a date prior to the identification of any amyloid protein. Forty-four participants discussed the intricacies of Congo red staining and reported on the discovery of P-component among other things. What a long way our Society has come! The XIIIth Symposium will focus on the process of fibril formation, mechanisms of cell damage in amyloid disease, emerging diagnostics and innovative therapeutics. It will be hosted by Dr. Bouke Hazenberg, Ingrid van Gameren, and Johan Bijzet. You attendance and participation are  welcome; abstracts may be submitted from October 31, 2011 until January 16, 2012. More information is available at the website.

In spite of the devastation caused by an earthquake and tsunami in Japan this past year, the VIIIth International Symposium on Familial Amyloidosis will take place in Kumamoto Japan November 20-22, 2011. The leaders are Prof. Yukio Ando and Honorary Prof. Shukuro Araki. The meeting will focus on amyloidogenesis of precursor proteins of FAP, pathogenesis of organ disorders in FAP, and management of patients, including novel therapeutic approaches. You are invited to attend and to submit abstracts (deadline Sept. 5, 2011). Please see the meeting website.

With best wishes.

Sincerely,

Martha Skinner, M.D.

President, International Society of Amyloidosis

*        *        *

 
Research Meeting about Amyloid Fibrils, Prions and Precursors: Molecules for Targeted Intervention 25-28 August 2011, Halle (Saale), Germany

Scope of the meeting: This conference deals with a group of human diseases that is characterized by the abnormal formation of amyloid fibrils or prions. Examples hereof include neurodegenerative disorders, such as Alzheimer's, Parkinson's and Creutzfeldt-Jakob, as well as the systemic amyloidoses, such as AA and ATTR amyloidosis.

The conference focuses on the development and characterization of small molecules (natural compounds, synthetic molecules, etc.) or proteins (antibodies, artificial binding proteins...), which bind to certain structural states and may be used for the purposes of detection, diagnosis or interference.

Invited lectures will be delivered by world-renowned experts on systemic or neurodegenerative amyloidoses and from biophysicists, who develop new ligands targeting amyloid fibrils, prions or their structural precursors. Additional short talks will be selected from the abstracts / registrations.

Registration: Short talks will be selected after 30th June 2011. Spaces are limited and will be filled first come first serve. Early registration is recommended. Prize discounts for early-bird registrations apply. Registration begins on the 10th January 2011.

*        *        *

 
Announcement by the President:

January 2011

Dear Colleagues,

Best wishes for 2011. I write to update you on news of International Society of Amyloidosis and urge you to stay informed by visiting our website at: http://www.amyloidosis.nl. I hope you have continued your membership this year and will invite your colleagues to join. Your membership supports the ISA International meetings and insures continued publication of the Amyloid journal. Directions for joining are found on our website. In a small Society every member counts!

I am happy to report that our journal, under the editorship of Per Westermark, is off to a good start. The latest issue publishes the 2010 report of the Nomenclature Committee and it is offered by Informa as a free open access on-line article. You will find it by going to http://informahealthcare.com/amy and clicking on current issue. Please read it and pass it on to your colleagues. It is important to use standard nomenclature in publications to be sure we have a universal understanding as we report on various types of amyloidosis.

I urge you to submit your manuscripts to our Amyloid journal. It has a new on-line submission and review process and promises to have faster turnaround and publication times. You can access directions for on-line submission on our website. Recently, we have been made aware of new companies planning to start on-line publication of research articles on amyloidosis. I remind you that the amyloid field is small and this is a critical period for our journal. Any decrease in good research articles going to our Amyloid journal could have very serious effects.

Save the date for the XIIIth International Symposium on Amyloidosis! Plans are moving forward and the Symposium will take place at the University Medical Center of Groningen, the Netherlands May 6-10, 2012. The Symposium, “From misfolded proteins to well-designed treatment” will be hosted by Dr. Bouke Hazenberg and his colleagues. Additional information will be on the website soon.

The VIIIth International Symposium on Familial Amyloidosis will take place November 20-23, 2011 at the Kumamoto City International Center in Kumamoto Japan. It will be hosted by Dr. Yukio Ando and his colleagues. Additional information will be on our website.

Finally, I want you to know that during this year we will be considering sites for the XIVth International Symposium on Amyloidosis for 2014. Given the pace of research, the Society hopes to continue meeting on an every other year basis. If you and your colleagues have an interest in hosting the next meeting please contact us.

With best wishes for a good year in amyloid research.

Sincerely,

 

 

*        *        *

 
Announcement by the President:

September, 2010

Dear ISA Colleagues,

Just a quick note to let you know some good news re: our official journal, AMYLOID: Journal of Protein Folding Disorders. I urge you to consider our Society's journal when you submit your next manuscript. Please note the new online submission policy. This year, the impact factor climbed again to 2.115, and we have recently appointed a new editor-in-chief to spearhead the 2011 volume, Prof. Per Westermark. To further add to this, the journal has a new submission portal to make manuscript processing (and submitting) swift and simple.

With best wishes, Martha Skinner

*        *        *

 

Letter from the President:

July, 2010

Dear Colleagues:

It was wonderful to see so many of you at XIIth Symposium on Amyloidosis in Rome last April. And those of you who couldn’t make it because of the volcanic ash were sorely missed. In spite of unforeseen natural disaster, the Symposium was still the biggest and best ever. Giampaolo Merlini and his colleagues are to be congratulated on such an outstanding meeting. The high quality of the presentations, the fine hotel accommodations, the banquet dinner, and smooth organization of all events happened because of enormous effort behind the scene.

I have two important things to tell you about. First, let me give you some very good news about the next meeting. Bouke Hazenberg has offered to host the XIIIth Symposium in Groningen. Those of you who were in Rome may be confused as you remember the offer by Mark Pepys to host the next symposium in London. Unfortunately, the London group will not be able to host the XIIIth, although we hope circumstances will allow them to host a future meeting. Bouke will give us more details on the Groningen meeting soon.

Secondly, I want to bring you up to date about our journal. During the last 2 years the Society negotiated ownership of the Amyloid Journal from the publisher. This was important as the Journal, now in its 17th year, is older than the Society and belonged to the publisher. As you may know, the Journal was the brainchild of Dr. Alan Cohen who has been its editor for the past 17 and one half years. It has flourished with quarterly issues of countless key publications and, importantly, the Journal kept us linked as a group even before the Society was formed. Alan retires from the Journal this summer. We are grateful for his wise leadership in founding the Journal and his skilled editorship.

Per Westermark has graciously offered to take over as the Amyloid Journal Editor and the new headquarters will be in Uppsala, Sweden. We are confident that expert editing will continue. This is a good time to write papers on the research presented at the Rome meeting. I urge you to send Per your manuscripts so we can maintain the Journal’s high quality publications. Per tells us there is an immediate need for good manuscripts! An electronic submission system will soon be introduced, probably in August. We expect that this will increase efficiency in the handling of the papers.

I have been astonished at the fast pace of new amyloid basic and clinical research and pleased that it is leading to the subsequent development of new therapies for amyloidosis. This is a long hoped for accomplishment for those of us who have worked in the amyloid field for a long time.
We have reached the point where good treatments are available for some of the amyloid diseases and more are on the way. Many people suffering with amyloidosis are getting better. For us as a Society, there is now a greater need for collaborative research and for multicenter treatment trials.

Your membership in the Society is important. Accelerated progress in research and treatment will be accomplished as members of our Society to work together. To help with our goal, the ISA has a new website created by Bouke Hazenberg (www.amyloidosis.nl ). Through this website you will be kept informed about the ISA with news of society business and events, details on membership and subscription to the Journal, amyloid grant opportunities, and other issues.

We welcome you ideas on how the Society can serve you.

Wishing you a good summer,


Martha Skinner

 

 

*        *        *

 

Announcement by the Secretary:

 

The XIIth International Symposium on Amyloidosis has been held in Rome from 18-21 April 2010. At this meeting a new Board of Directors of the ISA was elected for the next period. The President Giampaolo Merlini has become Past President and the Vice President Martha Skinner is the new President. Merrill Benson was elected Vice President, Laura Obici was elected Secretary, Angela Dispenzieri was elected Treasurer, and Bouke Hazenberg, Giovanni Palldini and David Seldin were elected Members at large. The ballot for these members of the new Board was held at the business meeting in Rome on Wednesday April 21. At this business meeting also a proposal for modification and adaptation of the Constitution & Rules and Bylaws was discussed and approved by a two-thirds majority.

 

 

*        *        *

 

 

 

Professor dr. Enno Mandema, chairman of the first International Symposium on Amyloidosis in Groningen in 1967, passed away at the end of January 2010. He was 88 years old and during his whole life he remained interested in all developments in the field of amyloid and amyloidosis. We will remember him as one of the founding fathers of our amyloidosis community and, most of all, as a good amyloid friend.

 

prof.dr. E. Mandema, juni 2008

Professor Enno Mandema, June 2008

*        *        *

 

On Saturday 2 May 2009 the new German Amyloidosis Centre was opened with a symposium. The foundation of this centre is an encouraging development that will increase the quality of care for patients with amyloidosis in Europe!

*        *        *

 
In December 2006 a European research consortium (EURAMY) started in Uppsala with a three year collaboration of 12 institutes from 8 European countries, called: Systemic Amyloidosis in Europe. This research project is granted by the Eurpean Communion as part of the 6th Framework Programme and deals with amyloidosis from basic science to clinical studies.